Bharde A, Nadagouda S, Dongare M, Hariramani K, Basavalingegowda M, Haldar S
J Liq Biopsy. 2025; 7:100284.
PMID: 40027235
PMC: 11863978.
DOI: 10.1016/j.jlb.2024.100284.
Qu J, Wang M, Gao Y, Zhang H
Cancer Inform. 2025; 24:11769351251316398.
PMID: 39902175
PMC: 11789128.
DOI: 10.1177/11769351251316398.
Lee S, Ricci B, Tran J, Eul E, Ye J, Ren Q
Nat Commun. 2025; 16(1):1183.
PMID: 39885132
PMC: 11782527.
DOI: 10.1038/s41467-025-56420-w.
Dent S, Guha A, Moore H, Makari D, McCaleb R, Arias I
Cardiooncology. 2025; 11(1):7.
PMID: 39871392
PMC: 11771012.
DOI: 10.1186/s40959-025-00305-w.
Wehbe S, Firkins S, Sweeney J, Moore H, Rouphael C
ACG Case Rep J. 2025; 12(1):e01582.
PMID: 39829946
PMC: 11741208.
DOI: 10.14309/crj.0000000000001582.
The Cost-Effectiveness of CDK4/6 Inhibitors in Treating HR+/HER2- Metastatic Breast Cancer Patients in the USA: When Non-medication Expenses are Considered.
Pilehvari A, You W, Kimmick G, Camacho F, Bonilla G, Anderson R
Clin Drug Investig. 2025; 45(2):59-68.
PMID: 39797932
DOI: 10.1007/s40261-024-01416-5.
Synergistic Effects of Mistletoe Lectin and Cisplatin on Triple-Negative Breast Cancer Cells: Insights from 2D and 3D In Vitro Models.
Lyu S, Meshesha S, Hong C
Int J Mol Sci. 2025; 26(1.
PMID: 39796221
PMC: 11719730.
DOI: 10.3390/ijms26010366.
Disparities in treatment delays among metastatic breast cancer patients: insights from nationwide electronic health records, 2011-2022.
Pilehvari A, You W, Kimmick G, Bonilla G, Anderson R
Breast Cancer Res Treat. 2025; .
PMID: 39762708
DOI: 10.1007/s10549-024-07593-3.
The Multifaceted Roles of Myrrha in the Treatment of Breast Cancer: Potential Therapeutic Targets and Promises.
Shams A, Alzahrani A, Ayash T, Tamur S, Al-Mourgi M
Integr Cancer Ther. 2024; 23:15347354241309659.
PMID: 39707884
PMC: 11663268.
DOI: 10.1177/15347354241309659.
Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer.
Nguyen T, Mital S
Pharmacoeconomics. 2024; 43(3):351-361.
PMID: 39630382
DOI: 10.1007/s40273-024-01456-x.
Molecular Analysis of PIK3CA in Metastatic Hormone Receptor-Positive Breast Cancer in Chile: Clinical and Pathological Insights.
Araya C, Mino B, Le Cerf P, Gaete F, Armisen R, Carvajal-Hausdorf D
Int J Mol Sci. 2024; 25(22).
PMID: 39596311
PMC: 11594956.
DOI: 10.3390/ijms252212246.
Cell Populations in Human Breast Cancers are Molecularly and Biologically Distinct with Age.
Parsons A, Colon E, Spasic M, Kurt B, Swarbrick A, Freedman R
Res Sq. 2024; .
PMID: 39483921
PMC: 11527348.
DOI: 10.21203/rs.3.rs-5167339/v1.
Prediction model for survival of younger patients with breast cancer using the breast cancer public staging database.
Kang H, Ko M, Ryu K
Sci Rep. 2024; 14(1):25723.
PMID: 39468113
PMC: 11519337.
DOI: 10.1038/s41598-024-76331-y.
Disparities in receipt of 1- line CDK4/6 inhibitors with endocrine therapy for treatment of hormone receptor positive, HER2 negative metastatic breast cancer in the real-world setting.
Pilehvari A, Kimmick G, You W, Bonilla G, Anderson R
Breast Cancer Res. 2024; 26(1):144.
PMID: 39425174
PMC: 11488071.
DOI: 10.1186/s13058-024-01902-w.
Role of NOX1 and NOX5 in protein kinase C/reactive oxygen species‑mediated MMP‑9 activation and invasion in MCF‑7 breast cancer cells.
Song H, Kim J, Noh E, Youn H, Lee Y
Mol Med Rep. 2024; 30(4).
PMID: 39219290
PMC: 11350630.
DOI: 10.3892/mmr.2024.13312.
Drug Combination Nanoparticles Containing Gemcitabine and Paclitaxel Enable Orthotopic 4T1 Breast Tumor Regression.
Yu J, Xu X, Griffin J, Mu Q, Ho R
Cancers (Basel). 2024; 16(16).
PMID: 39199565
PMC: 11352501.
DOI: 10.3390/cancers16162792.
Development and Characterization of a Peptide-Bisphosphonate Nanoparticle for the Treatment of Breast Cancer.
Glass K, Fines C, Coulter P, Jena L, McCarthy H, Buckley N
Mol Pharm. 2024; 21(10):4970-4982.
PMID: 39196792
PMC: 11462496.
DOI: 10.1021/acs.molpharmaceut.4c00299.
Ex vivo model of breast cancer cell invasion in live lymph node tissue.
Morgaenko K, Arneja A, Ball A, Putelo A, Munson J, Rutkowski M
bioRxiv. 2024; .
PMID: 39091774
PMC: 11291011.
DOI: 10.1101/2024.07.18.601753.
Quantitative proteomics reveals serum proteome alterations during metastatic disease progression in breast cancer patients.
Kaur J, Jung S, Austdal M, Arun A, Helland T, Mellgren G
Clin Proteomics. 2024; 21(1):52.
PMID: 39075362
PMC: 11285292.
DOI: 10.1186/s12014-024-09496-3.
Organ-Specific Immune Setpoints Underlie Divergent Immune Profiles across Metastatic Sites in Breast Cancer.
Egelston C, Guo W, Simons D, Ye J, Avalos C, Solomon S
Cancer Immunol Res. 2024; 12(11):1559-1573.
PMID: 39051632
PMC: 11534553.
DOI: 10.1158/2326-6066.CIR-23-0718.